COX-2 and neurodegeneration in Parkinson's disease.
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Recent observations link cyclooxygenase type-2 (COX-2) to the progression of the disease. Consistent with this notion, studies with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) show that inhibition and ablation of COX-2 markedly reduce the deleterious effects of this toxin on the nigrostriatal pathway. The similarity between this experimental model and PD strongly supports the possibility that COX-2 expression is also pathogenic in PD.
Teismann
P
P
Neuroscience Research Laboratories of the Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA.
Vila
M
M
Choi
D-K
DK
Tieu
K
K
Wu
D C
DC
Jackson-Lewis
V
V
Przedborski
S
S
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D051546:Cyclooxygenase 2; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism*; D020267:MPTP Poisoning / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D000077239:Meloxicam; D008565:Membrane Proteins; D051379:Mice; D009410:Nerve Degeneration / Q000209:etiology*; D010300:Parkinson Disease / Q000201:enzymology / Q000503:physiopathology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D013378:Substantia Nigra / Q000293:injuries / Q000503:physiopathology; D013843:Thiazines / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D007527:Isoenzymes; D008565:Membrane Proteins; D013843:Thiazines; D013844:Thiazoles; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000077239:Meloxicam